Fráncfort (Alemania), 13 sep (EFE).- El principal selectivo de la Bolsa de Fráncfort, el DAX 40, subió un 0,98 % este viernes ...

Nueva York, 9 sep (EFE).- Wall Street cerró este lunes en verde y el Dow Jones de Industriales, su principal indicador, subía ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

The trial will assess the asset in patients with diabetic macular oedema. Credit: NTshutterth / Shutterstock. MSD (Merck & Co) and its wholly-owned subsidiary EyeBio have announced the start of the ...

Credit: R Photography Background/Shutterstock. Merck & Co has received European Commission (EC) approval for the use of Keytruda (pembrolizumab) along with Padcev (enfortumab vedotin-ejfv) as a ...

It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 5.6% over the past three months. But if you pay close attention, you might find that ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.

RAHWAY, N.J., August 29, 2024--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today provided updates on two Phase 3 trials, KEYNOTE-867 and KEYNOTE-630.

Image credit: JeanLucIchard via Shutterstock Merck & Co (MSD) has announced that it is discontinuing two Phase III Keytruda (pembrolizumab) clinical trials. The KEYNOTE-867 (NCT03924869) trial was ...

Migrar y Desaparecer', un especial periodístico de Univision Dallas Fort Worth, encontró que falta cooperación entre los gobiernos de Estados Unidos, México y Guatemala para la búsqueda de ...

Qué pasa en la actualidad con el billete de Q1? En Guatemala, continúa la circulación de las monedas de Q1. En 2022, se informó que los billetes de esa denominación dejarían de circular a ...